Granisetron-d6

Granisetron-d6 (BRL 43694-d6) is deuterium labeled Granisetron. Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.

1224925-80-7

BRL 43694-d6

12352005

5-HT Receptor; Isotope-Labeled Compounds

GPCR/G Protein; Neuronal Signaling; Others

Cancer-programmed cell death

Neurological Disease; Cancer

O=C(C1=NN(C([2H])([2H])[2H])C2=CC=CC=C12)N[C@H]3C[C@]4([H])N(C([2H])([2H])[2H])[C@](CCC4)([H])C3

C18H18D6N4O

318.45

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Sanger GJ, Nelson DR. Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron) . Eur J Pharmacol. 1989 Jan 10;159 (2) :113-24.|[3]Maleki-Dizaji N, Eteraf-Oskouei T, Fakhrjou A, The effects of 5HT3 receptor antagonist granisetron on inflammatory parameters and angiogenesis in the air-pouch model of inflammation. Int Immunopharmacol. 2010 Sep;10 (9) :1010-6.|[4]Boccia RV, Gordan LN, Clark G, Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011 Oct;19 (10) :1609-17.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B0071S2/

Isotope-Labeled Compounds

No Development Reported